title: Predictive gene signatures for bevacizumab and cetuximab as well as cytotoxic agents.
authors.affiliation: Oncotest GmbH, Institute for Experimental Oncology, Freiburg, Germany. Fiebig@Oncotest.de
authors.forename: Heinz-Herbert
authors.initials: HH
authors.lastname: Fiebig
authors.forename: Vincent
authors.initials: V
authors.lastname: Vuaroqueaux
authors.forename: Andre
authors.initials: A
authors.lastname: Korrat
authors.forename: Frederic
authors.initials: F
authors.lastname: Foucault
authors.forename: Thomas
authors.initials: T
authors.lastname: Beckers
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000494:pharmacology*; D000068258:Bevacizumab; D000068818:Cetuximab; D005240:Feasibility Studies; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects*; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics; D023041:Xenograft Model Antitumor Assays
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068258:Bevacizumab; D000068818:Cetuximab